Botulinum toxin manufacturers

Manufacturer context explains how botulinum toxin products reach the market. This hub includes toxin makers, franchise owners, parent-company anchors, and commercialization partners when they help explain a product’s identity or market path.

A brand may be developed by one company, manufactured by another, commercialized through a partner, named differently across regions, or interpreted through litigation, manufacturing, and regulatory history. The manufacturer profiles connect those relationships without implying that one company or product is clinically superior.

Manufacturer Directory

Manufacturer / market node	Country / base	Public status	Scale / market signal
AbbVie / Allergan	United States	Public; NYSE: ABBV	Corporate and franchise anchor behind Botox, with Allergan’s product history now inside AbbVie’s therapeutic and aesthetics portfolio.
Ipsen	France	Public; Euronext Paris	Multinational specialty-care company with Dysport as a major type A toxin product.
Galderma	Switzerland	Public; SIX: GALD	Aesthetic commercialization partner for Dysport in licensed territories and developer of Relfydess.
Merz Pharma	Germany	Private	Privately held healthcare and aesthetics group with Xeomin as its main toxin reference product.
Daewoong Pharmaceutical	South Korea	Public; KRX: 069620	Korea-listed pharmaceutical company with Nabota / Jeuveau as an international toxin product line.
Evolus	United States	Public; Nasdaq: EOLS	Commercialization company for Jeuveau in the United States and Nuceiva in selected international markets.
Hugel	South Korea	Public; KOSDAQ: 145020	Korea-listed medical-aesthetics company with Botulax / Letybo central to its toxin-market identity.
Medytox	South Korea	Public; KOSDAQ: 086900	Korea-listed biopharma company with multiple type A toxin product lines.
Revance / Crown Laboratories	United States	Private	Daxxify development history and current ownership context following Crown’s 2025 acquisition of Revance.
Supernus Pharmaceuticals	United States	Public; Nasdaq: SUPN	Current commercial portfolio company for the type B product Myobloc.

Manufacturer Reading Map

Manufacturer profiles are most useful when they separate facts that are often compressed in public discussion. Some profiles are factory-level manufacturing nodes; others are franchise, parent-company, or commercialization nodes that explain why a familiar brand appears in a market.

Manufacturer question	Current graph examples
Which manufacturer or company sits behind a familiar brand?	AbbVie / Allergan connects to Botox, Revance / Crown to Daxxify, and Supernus to Myobloc.
When does one product family use different market names?	Daewoong Pharmaceutical and Evolus connect Nabota, Jeuveau, and Nuceiva; Hugel connects Botulax and Letybo.
Which pages need manufacturing context?	Daewoong, Hugel, and Medytox include Korean facility context where it helps explain product origin, manufacturing footprint, or market structure.
Where do licensing, acquisition, or development roles matter?	Galderma separates Dysport commercialization from Relfydess development; Revance / Crown preserves Daxxify’s development and ownership history.

Comparison Pathways

The manufacturer graph supports product comparison, but it is not a ranking system. Brands provide product-level entries for Botox, Dysport, Xeomin, Jeuveau, Daxxify, Letybo, and Myobloc / Neurobloc. Botulinum toxin explains the medicine family, while type A vs type B separates serotype biology from brand identity.

Korean manufacturers deserve profile-level coverage because Daewoong, Hugel, and Medytox now shape product availability, export naming, litigation history, and U.S. comparison conversations. Their pages should not be read as proof that all Korean toxin products share the same approval status, label, formulation, or unit system.